Contineum Therapeutics, Inc. (CTNM) fair value analysis
Nasdaq · Updated 2026-10-19
CTNM price how computed
Valuation status
No fair-value estimate yetCTNM has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for CTNM yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $7.08
- Sector
- Healthcare
- 12-month range
- $7.08–$17.57
- Market cap
- $233M
- From 52-week high
- -59.7%
- Shares outstanding
- 33M
- Rank in Healthcare by quality score
- #232 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Contineum Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders. The company operates in the United States and conducts research and development activities aimed at advancing its pipeline of therapeutic candidates.
CTNM currently ranks #232 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $233M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-1.73
- Debt / equity
- 0.03
- Shares outstanding
- 33M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 23 · oversold
- 50-day average
- $13.98
- 200-day average
- $13.64
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-29
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+13.0%)
2026-03 ▲ beat (+26.4%)
2025-12 ▲ beat (+24.6%)
2025-09 ▲ beat (+2.2%)
2025-06 ▼ miss (-51.2%)
2025-03 ▼ miss (-8.8%)
2024-12 ▼ miss (-30.2%)
2024-09 ▲ beat (+4.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $22.1
- Target vs last price
- +212.1%
What our data shows for CTNM
- Shares are trading in the lower third of their 12-month price range of $7.08–$17.57.
- The 14-day relative strength index sits at an oversold 23.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CTNM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the CTNM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for CTNM showed a shift in the Relative Strength Index this week, moving from the neutral zone into oversold territory. The stock's current valuation verdict remains pending full valuation analysis. No other indicator changes were recorded for the Healthcare sector company during this period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for CTNM showed a shift in momentum this week as the Relative Strength Index moved from oversold territory into neutral zone. The healthcare company's valuation remains under review pending complete analysis. No additional technical indicator changes were recorded for the week.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CTNM stock undervalued?
TickrTrends has no fair-value estimate for CTNM yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is CTNM's TickrTrends verdict?
CTNM is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does CTNM compare to other Healthcare stocks?
CTNM ranks #232 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CTNM overbought or oversold?
CTNM's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does CTNM report earnings next?
CTNM's next earnings report is scheduled for 2026-10-29, per the published earnings calendar.
Does CTNM usually beat earnings estimates?
Over its last 8 reported quarters CTNM beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CTNM?
Of 8 analysts covering CTNM, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $22.1 (+212.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.